Advanced Heart Health Panel

A standard cholesterol test gives you four or five numbers. Those numbers matter, but they tell only part of the story. You can have normal LDL cholesterol and still carry serious cardiovascular risk from inflammation, insulin resistance, a genetically elevated particle called lipoprotein(a), or early liver and kidney stress that quietly accelerates artery damage. This panel pulls those blind spots into a single blood draw.

By combining lipid particle counts, an inflammatory marker, metabolic markers, and organ function tests, the Advanced Heart Health Panel answers a question that no single test can: where is your cardiovascular risk actually coming from? That answer changes what you do about it.

What This Panel Reveals

The tests in this panel cover four distinct domains of cardiovascular risk. Each domain can be the primary driver of a heart attack or stroke, and each can be present while the others look perfectly normal. Checking all four at once is what makes this panel worth more than ordering any single test in isolation.

Lipid and Particle Risk

The standard lipid markers (LDL, HDL, VLDL, and triglycerides) tell you how much cholesterol is circulating and in what fractions. But the amount of cholesterol inside a particle is not the same as the number of particles hitting your artery walls. ApoB (apolipoprotein B) counts the total number of particles that can cause plaque buildup, including LDL, VLDL, and others. In pooled data from large prospective studies, ApoB predicted coronary events more accurately than LDL cholesterol in the majority of head-to-head comparisons.

Lipoprotein(a), often written as Lp(a), is a genetically determined particle that most standard panels skip entirely. In a pooled analysis of 36 prospective studies covering more than 126,000 people, higher Lp(a) concentration was continuously associated with greater coronary heart disease risk, independent of all conventional risk factors. Because Lp(a) is largely set by your genes, it does not respond to diet or most medications, which makes knowing your level the first step toward targeted prevention.

Inflammatory Risk

High-sensitivity C-reactive protein (hs-CRP) measures low-grade inflammation in your blood vessels. Artery damage is not just about cholesterol deposits; it is also about how inflamed those deposits become. The JUPITER trial enrolled nearly 18,000 adults with normal LDL cholesterol but elevated hs-CRP and showed that treating the inflammation and lipid combination reduced major cardiovascular events by 44%.

The CANTOS trial went further, using a drug that lowered inflammation without changing cholesterol at all. Participants treated with the anti-inflammatory drug had a 15% reduction in heart attacks, strokes, and cardiovascular death. These two trials together proved that inflammation is an independent engine of cardiovascular disease, not merely a bystander. If your cholesterol looks fine but your hs-CRP is elevated, you still have work to do.

Metabolic Risk

Blood sugar problems do not start with diabetes. They start years earlier, when insulin levels begin rising to compensate for cells that are becoming resistant. This panel includes fasting glucose, fasting insulin, and HbA1c (a measure of your average blood sugar over the previous two to three months) to catch that trajectory early.

In the Atherosclerosis Risk in Communities study of more than 11,000 non-diabetic adults, higher HbA1c was strongly associated with coronary heart disease and death from any cause over 14 years of follow-up, even at levels well below the diabetes threshold. Fasting insulin adds a layer that HbA1c misses: it reveals whether your pancreas is already working harder than it should, even when blood sugar still appears normal.

Organ Function and Electrolyte Balance

Heart disease does not happen in a vacuum. Your liver processes cholesterol, clears inflammatory proteins, and metabolizes medications. Your kidneys filter waste and regulate blood pressure. Electrolytes govern the electrical signals that keep your heart beating in rhythm. This panel includes liver enzymes, kidney waste markers, and a full electrolyte set because dysfunction in any of these systems amplifies cardiovascular risk.

Elevated liver enzymes, specifically ALT (alanine aminotransferase) and AST (aspartate aminotransferase), often signal fatty liver disease. A meta-analysis found that non-alcoholic fatty liver disease (NAFLD) was associated with a 64% increased risk of fatal and non-fatal cardiovascular events, independent of traditional risk factors. Kidney function, assessed here through creatinine and BUN (blood urea nitrogen), is similarly tied to heart outcomes. Data from the CKD Prognosis Consortium showed that even mildly reduced kidney filtration rates independently predict cardiovascular death.

How to Read Your Results Together

Individual results matter, but the real power of this panel is in patterns. Two people can have the same LDL cholesterol and face vastly different risk depending on what the rest of the panel shows. Here are the most actionable patterns to look for.

When Results Can Be Misleading

Acute illness, recent infection, or surgery can raise hs-CRP into the 10 to 100 mg/L range, far above the cardiovascular risk threshold. If your hs-CRP comes back above 10 mg/L, it likely reflects a short-term inflammatory event rather than chronic vascular inflammation. Wait two to three weeks and retest.

Fasting status affects glucose, insulin, and triglycerides. If you ate within 8 hours of the draw, those results may look artificially high. A non-fasting triglyceride over 200 mg/dL still warrants attention, but the full picture is clearest with a 10 to 12 hour fast. Vigorous exercise in the 24 hours before the draw can also temporarily elevate liver enzymes (AST in particular) and creatinine.

Dehydration can concentrate blood and push creatinine, BUN, and electrolytes outside their normal range without any underlying organ problem. If kidney markers are borderline, hydrate normally and retest before drawing conclusions.

Tracking Over Time

A single snapshot tells you where you stand today. Serial testing every 6 to 12 months reveals direction and velocity. A fasting insulin that climbs from 6 to 12 to 18 over three draws tells a story that any single result would miss. The same is true for hs-CRP and ApoB: a number that sits stubbornly above target despite intervention signals the need to change course.

Lp(a) is the exception. Because it is genetically determined and largely stable over a lifetime, a single measurement is usually sufficient. If your first result is above 50 mg/dL (or 125 nmol/L), you have your answer. Repeat testing is warranted only if you start a therapy specifically designed to lower Lp(a).

For the metabolic markers, trending matters more than any single threshold. An HbA1c of 5.4% that was 5.0% two years ago is more concerning than a stable 5.6% that has not budged in five years. Track the slope, not just the snapshot.

What to Do with Your Results

If the lipid markers, hs-CRP, and metabolic markers are all in range, you have strong evidence that your cardiovascular risk is low. Retest annually to confirm the trajectory holds.

If ApoB or Lp(a) is elevated, consult a cardiologist or lipid specialist. ApoB responds to statins, PCSK9 inhibitors (a newer class of cholesterol-lowering medication), and lifestyle changes. Lp(a) does not respond meaningfully to lifestyle, but knowing your level lets you and your physician manage every other modifiable risk factor more aggressively.

If hs-CRP is persistently above 2.0 mg/L on repeat testing, this is residual inflammatory risk that should not be ignored. Anti-inflammatory lifestyle strategies, such as reducing belly fat, improving sleep, and exercising regularly, are the recommended starting point, with medication options for higher-risk individuals.

If the metabolic trio (glucose, insulin, HbA1c) shows early insulin resistance, act before the numbers cross into prediabetes. Strength training, reducing refined carbohydrates, and improving body composition are the most effective interventions. If liver enzymes are elevated alongside these metabolic markers, request a liver ultrasound to evaluate for fatty liver disease, which is both a consequence and an accelerator of cardiovascular risk.